COMPANY INFO
HistoSonics, Inc. is a privately held medical equipment manufacturing company founded in 2009 by scientists and engineers from the University of Michigan who developed the science of histotripsy. The company has around 214 employees and is headquartered in Plymouth, Minnesota. HistoSonics develops a non-invasive sonic beam therapy platform that uses focused ultrasound to mechanically destroy unwanted tissue and tumors, aiming to bring histotripsy into everyday clinical practice. Its industry is medical devices, specifically focused on non-invasive therapeutic technologies. The official website is https://histosonics.com.
HistoSonics, Inc. is a leading medical equipment manufacturing company founded in 2009 by a team of scientists and engineers from the University of Michigan. Headquartered in Plymouth, Minnesota, with additional office locations in Ann Arbor and Minneapolis, HistoSonics develops cutting-edge non-invasive therapeutic technologies. Their flagship offering is a sonic beam therapy platform using focused ultrasound (called “histotripsy”) to mechanically destroy unwanted tissue and tumors. With a current team of over 200 employees, HistoSonics is quickly advancing the adoption of histotripsy in everyday clinical practice, serving the medical devices industry and striving to transform the standard of tumor treatment worldwide.
HistoSonics, Inc. funding totals approximately $334.57 million over 14 rounds, making them one of the most well-capitalized innovators in the medical devices sector focused on non-invasive therapeutic technologies. The company’s funding strategy has been marked by sizable Series C and Series D rounds, a blend of venture capital and debt financing, and participation from prominent industry, venture, and strategic investors. HistoSonics investors include healthcare VCs, multinational medical device corporations, and esteemed angel investors. Key milestones in HistoSonics funding history include FDA De Novo clearance for their Edison System and large infusions of capital to commercialize, advance clinical trials, and support global market growth.
This recent Series D round will accelerate advancements to HistoSonics’ non-invasive histotripsy platforms, support US and global commercial growth, and initiate the pivotal BOOMBOX Master Study for liver tumor treatment using the Edison System, which attained FDA De Novo clearance in October 2023.
This Series D round aimed to continue funding product development and expand the market reach of HistoSonics' innovative histotripsy therapy platforms, deepening their clinical and commercial momentum.
Debt financing from Signature Bank was secured to back HistoSonics' operational scalability and growth needs, allowing the company flexibility as it advanced product development.
The Series C round powered the next generation of product development and supported clinical trials, paving the way toward expanded clinical applications and regulatory approvals.
This earlier Series C infusion backed clinical development and early commercialization efforts as HistoSonics began to establish its technology in the field.
HistoSonics’ Series A round provided essential capital for initial product development and early commercialization, marking the company’s entrance onto the medical technology scene.
Alpha Wave Global is an international investment fund known for supporting high-growth technology and healthcare companies. As a lead investor in HistoSonics’ $102 million Series D round, Alpha Wave Global plays a vital role in fueling the company’s global growth and technological development.
Amzak Health is a healthcare-focused investor backing companies at the forefront of medical innovation. Their involvement in HistoSonics funding rounds brings extensive industry expertise and financial support to the company’s commercialization and clinical trial efforts.
Johnson & Johnson Innovation is the strategic venture arm of Johnson & Johnson, investing in breakthrough medical device technologies. As a recurring lead investor, J&J Innovation provides not only financial investment but also sector expertise and strategic partnership potential for HistoSonics.
Venture Investors is a venture capital firm specializing in healthcare companies. Venture Investors has supported HistoSonics since the early stages, including as lead in the Series A, and has continued its participation through multiple rounds, underscoring long-term confidence in HistoSonics’ vision.
As a provider of debt financing, Signature Bank contributed to HistoSonics' operational flexibility with a $15 million loan facility to support ongoing growth initiatives.
Yonjin Capital is a venture capital firm with a strong focus on medical technologies. Yonjin Capital co-led the Series C round, providing significant capital to advance histotripsy clinical trials and product development.
A global leader in cancer care solutions, Varian Medical Systems has not only invested in HistoSonics but also brings extensive commercialization and industry insight, further strengthening HistoSonics’ strategic position.
Lumira Ventures specializes in life sciences and health technology investing. As a co-lead investor in multiple rounds, Lumira supports HistoSonics’ growth with deep sector expertise and network connections.
Fred Moll is widely recognized as a pioneer in the development of robotic medical devices and has been an active angel investor in transformative medical technology companies. His early involvement signals strong technical validation and belief in HistoSonics’ innovation.
Websets is a powerful natural language search and data enrichment tool that helps you discover comprehensive funding information for any company. Whether you're researching HistoSonics, Inc. funding rounds or exploring investment data for other companies, Websets provides detailed insights into funding history, investors, and financial milestones.
With Websets, you can access detailed funding profiles, investor information, and financial data through intuitive natural language queries. Sign up now to enhance your funding research capabilities.